A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment by Snoeren, N. et al.
STUDY PROTOCOL Open Access
A randomized two arm phase III study in patients
post radical resection of liver metastases of
colorectal cancer to investigate bevacizumab in
combination with capecitabine plus oxaliplatin
(CAPOX) vs CAPOX alone as adjuvant treatment
Nikol Snoeren1, Emile E Voest2*, Andre M Bergman3, Otilia Dalesio4, Henk M Verheul5, Rob AEM Tollenaar6,
Joost RM van der Sijp7, Sander B Schouten1, Inne HM Borel Rinkes1, R van Hillegersberg1
Abstract
Background: About 50% of patients with colorectal cancer are destined to develop hepatic metastases. Radical
resection is the most effective treatment for patients with colorectal liver metastases offering five year survival rates
between 36-60%. Unfortunately only 20% of patients are resectable at time of presentation. Radiofrequency
ablation is an alternative treatment option for irresectable colorectal liver metastases with reported 5 year survival
rates of 18-30%. Most patients will develop local or distant recurrences after surgery, possibly due to the outgrowth
of micrometastases present at the time of liver surgery. This study aims to achieve an improved disease free
survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the
angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX.
Methods/design: The Hepatica study is a two-arm, multicenter, randomized, comparative efficacy and safety study.
Patients are assessed no more than 8 weeks before surgery with CEA measurement and CT scanning of the chest
and abdomen. Patients will be randomized after resection or resection combined with RFA to receive CAPOX and
Bevacizumab or CAPOX alone. Adjuvant treatment will be initiated between 4 and 8 weeks after metastasectomy
or resection in combination with RFA. In both arms patients will be assessed for recurrence/new occurrence of
colorectal cancer by chest CT, abdominal CT and CEA measurement. Patients will be assessed after surgery but
before randomization, thereafter every three months after surgery in the first two years and every 6 months until 5
years after surgery. In case of a confirmed recurrence/appearance of new colorectal cancer, patients can be treated
with surgery or any subsequent line of chemotherapy and will be followed for survival until the end of study
follow up period as well. The primary endpoint is disease free survival. Secondary endpoints are overall survival,
safety and quality of life.
Conclusion: The HEPATICA study is designed to demonstrate a disease free survival benefit by adding
bevacizumab to an adjuvant regime of CAPOX in patients with colorectal liver metastases undergoing a radical
resection or resection in combination with RFA.
Trial Registration: ClinicalTrials.gov Identifier NCT00394992.
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Background
Colorectal cancer (CRC) is the second leading cause of
cancer-related-deaths in the western world. The incidence
of CRC is still increasing [1-3]. About 50% of patients with
progressed colorectal cancer develop liver metastasis [4].
The pathway from colon to liver metastases is via the
portal vein and liver metastases are usually the first metas-
tases to appear, often without signs of systemic dissemina-
tion meaning possibility of cure for these patients [5]. The
median survival of patients with colorectal liver metastases
is 6-12 months if untreated [6,7]. Complete surgical resec-
tion is the only treatment modality that offers hope for
cure, resulting in 5 year survival for 36-60% [8-11].
Improved imaging, and surgical techniques as well as
neoadjuvant therapy have increased the number of
patients receiving R0 resection for colorectal liver metasta-
sis. R0 resection is defined as a resection with tumor free
margins as confirmed by the pathologist. Liver resection is
a relatively safe procedure with mortality rates less that 5%
[12,13]. Unfortunately only approximately 25% of patients
are resectable at time of presentation. Radiofrequency
ablation (RFA) is an alternative treatment option with pro-
mising five year survival rates for patients with small (<4
cm) colorectal liver metastases. There are few studies
reporting long term survival after RFA ranging from 18-
30% [14-19]. The success rate of RFA greatly depends on
size and open approach of the tumors treated as shown in
a large meta-analysis examining 5224 treated tumors [20].
In all abovementioned studies, treated tumors had a mean
diameter of less than 5 cm and patients did not have more
than 3 tumors per patient on average. Surgical resection
or RFA of CRLM alone is obviously not sufficient as 40%-
70% of patients will develop local or distant recurrences
after surgery of colorectal liver metastasis.
Different clinical studies comparing surgery and sys-
temic adjuvant therapy with surgery and observation
demonstrate a benefit in disease free survival (DFS) for
the treatment arm [21-24]. Adding chemotherapy after
resection might prevent the outgrowth of micrometas-
tases present in the liver at the time of resection [25].
Portier and colleagues published the results of the first
randomized controlled phase III study comparing sur-
gery with observation with surgery and adjuvant che-
motherapy with 5 FU/LV, demonstrating a disease free
survival benefit for the systemic chemotherapy arm [24].
Chemotherapy regimens for advanced colorectal cancer
have improved. FOLFOX and CAPOX have proven to
be most effective regimens in the treatment of advanced
colorectal cancer. In the CAPOX regimen infusional 5
FU is replaced with the oral derivate capecitabine [26]
After resection or RFA, regeneration of the liver takes
place until the liver has reached its original volume. This
takes about 6 months till a year [27-29]. Directly after
liver resection, growth factors such as vascular endothe-
lial growth factor (VEGF), hepatocellular growth factor
(HGF), transforming growth factor (TGF), epidermal
growth factor (EGF), macrophage inflammatory protein
(MIP) en interleukine-6 (IL-6) are upregulated. Most of
these growth factors that play a role in liver regeneration
also are pro-angiogenic and involved with migration of
tumor cells and tumor growth. Because of this produc-
tion of many pro-angiogenic factors, the liver is a perfect
environment for angiogenesis and tumor growth. Because
small metastases (< 5 mm) are not detectable on CT
scanning, there is a chance that micrometastases are pre-
sent in the liver at the time of resection. Oxygen and
other nutrients reach the tumor cells by diffusion, how-
ever to exceed beyond 2 mm, a tumor needs its own
blood supply [30]. Pre-clinical studies demonstrate an
excessive increase in the growth of intra-hepatic and
extra-hepatic tumors after hepatectomy compared with
sham operated mice [25,31,32]. Adding an anti-angio-
genic target, such as bevacizumab, seems a logical next
step in the attempt to further improve disease free survi-
val (DFS) for patients with resected colorectal liver
metastases. Bevacizumab is a monoclonal antibody
against VEGF and has proven to be effective in patients
with metastatic colon cancer [33].
The effect of adjuvant therapy can not yet be measured
or predicted. In order to investigate the underlying
mechanisms of recurrence and to predict which patient
is most likely to benefit from adjuvant therapy, blood and
tissue will be collected during and after therapy.
Methods/design
Primary objective
To demonstrate a disease free survival benefit by adding
bevacizumab to an adjuvant regimen of CAPOX che-
motherapy in patients with colorectal liver metastases
undergoing radical resection or radical resection in com-
bination with RFA.
The disease free survival is defined as the interval
between randomization and recurrence of disease or
death, whatever occurs first.
Secondary objective
Secondary objectives are to compare survival, toxicity
and quality of life. Survival is defined as the interval
between randomization and death of any cause. The
grade of toxicity will be assessed using the NCI-CTC
criteria version 3.0. Quality of life will be studied by
means of the EORTC QLC C30.
Design
The Hepatica study is a two-arm, international, multicen-
ter, randomized, comparative efficacy and safety study
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comparing adjuvant CAPOX vs CAPOX and bevacizu-
mab in patients with resected or resected in combination
with ablated colorectal liver metastases. Randomization is
stratified according to clinical prognostication and treat-
ment site.
Stratification
Treatment assignment will be stratified, based on
(i) number (<4 or ≥4) of liver metastases;
(ii) metachronous or synchronous liver metastases;
(iii) prior adjuvant chemotherapy or no prior adjuvant
chemotherapy;
(iv) blood transfusion or no blood transfusion post
liver surgery;
(v) treatment site;
(vi) neoadjuvant treatment with 3 cycles of CAPOX;
(vii) use of RFA in combination with resection
Criteria for RFA:
-largest liver tumor </= 4 cm
-number of liver tumors </= 3.
Setting
Patients will be enrolled in 28 Dutch hospitals and 3
Swedish centers.
Eligibility criteria
Inclusion Criteria: In order to be eligible for the trial,
patients have to fulfil the following criteria:
1. Signed written informed consent obtained prior to
any study-specific procedure;
2. Age ≥ 18 years;
3. Liver metastases radically resected (R0 resection) or
liver metastases radically resected in combination with
RFA
Criteria for RFA:
-largest liver tumor </= 4 cm
-number of liver tumors </= 3;
4. Study medication started ≥ 4 and ≤ 8 weeks post
liver surgery;
5. Histologically confirmed liver metastasis of colorec-
tal cancer after surgery;
6. ECOG performance status 0 or 1 (Appendix 1);
7. Adequate hematology: neutrophils ≥ 1.5 × 109/L,
platelets ≥100 × 109/L, Hb ≥ 5.5 mmol/L, INR ≤ 1.5,
APTT < 1.5 × UNL;
8. Adequate biochemistry: total bilirubin ≤1.5 UNL,
ASAT and ALAT ≤ 2.5 × UNL, alkaline phosphatase ≤
2.5 × UNL, serum creatinin ≤ 1.5 UNL.
9. Urine dipstick < 2+ for protein.
Exclusion Criteria: Patients presenting with any of the
following criteria are not eligible for the study:
1 Extra-hepatic metastatic disease;
2 Adjuvant chemotherapy given <6 months prior to
detection of the liver metastases.
3 Chemotherapy for metastatic disease with the excep-
tion of max 3× CAPOX given as neoadjuvant therapy
max 6 weeks before resection of the colorectal liver
metastases;
4 Prior non colorectal malignancies, except adequately
treated basalioma of the skin or carcinoma in situ of the
cervix;
5 Bleeding diathesis or coagulation disorders or the
need for full-dose anticoagulation;
6. Major surgical procedure <4 weeks prior to start of
study treatment;
7. Radiofrequency ablation without resection;
8. Females with a positive pregnancy test (within
14 days before treatment start);
9. Lactating women;
10. Fertile women (<2 years after last menstruation)
and women of childbearing potential not willing to use
effective means of contraception;
11. History of psychiatric disability judged by the
investigator to be clinically significant, precluding
informed consent or interfering with compliance for
oral drug intake;
12. Clinically significant (i.e. active) cardiovascular dis-
ease e.g. cerebrovascular accidents (≤6 months prior to
randomization), myocardial infarction (≤1 year prior to
randomization), uncontrolled hypertension while receiv-
ing chronic medication, unstable angina, New York
Heart Association (NYHA) Grade II or greater conges-
tive heart failure, or serious cardiac arrhythmia requiring
medication;
13. Lack of physical integrity of the upper gastro-
intestinal tract, malabsorption syndrome, or inability to
take oral medication;
14. Known peripheral neuropathy, including oxalipla-
tin-induced neuropathy > grade 1. Absence of deep ten-
don reflexes as the sole neurological abnormality does
not render the patient ineligible;
15. Organ allografts requiring immunosuppressive
therapy;
16. Serious, non-healing wound, ulcer, or bone
fracture;
17. Chronic treatment with corticosteroids (dose of
≥10 mg/day methylprednisolone equivalent excluding
inhaled steroids);
18. Serious intercurrent infections (uncontrolled or
requiring treatment);
19. Current or recent (within the 28 days prior to ran-
domization) treatment with another investigational drug
or participation in another investigational study;
20. Patients with known allergy to Chinese hamster
Ovary cell proteins or other recombinant human or
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humanized antibodies or to any excipients of bevacizu-
mab formulation, platinum compounds or to any other
component of the study drugs.
Randomization
After having properly checked all eligibility criteria, stra-
tification parameters and having obtained patient’s writ-
ten informed consent, patients will be randomized by
fax at the Trial Office IKO Nijmegen (fax 024-3619080).
Randomized treatment will be confirmed by fax or
email within one (1) working day. Randomization takes
place wit TENALEA, this program uses a minimization
procedure.
Ethics
This study is to be conducted according to globally
accepted standards of Good Clinical Practice, and in
agreement with the latest revision of the Declaration of
Helsinki (2000, including the notes of clarification 2002
and 2004) and local regulations.
This protocol has been submitted and approved by
the Ethical Committee (EC) of the University Medical
Centre Utrecht http://www.umcutrecht.nl/MeTC and
the Central Committee on Research Involving Human
Subjects http://www.ccmo.nl in accordance with Dutch
legal requirements. The independent medical ethics
committees of all participating hospitals have approved
the study protocol.
Administrative changes to the protocol are minor cor-
rections and/or clarifications that have no impact on the
study conduct. The EC may be notified of administrative
changes at the discretion of the investigator. Oral and
written informed consent in form is obtained from all
patients prior to randomization.
Safety
All serious adverse events during the study period,
whether or not considered by the Investigator to be
related to study treatment, must be reported by fax to
the central data management office (Trial Office IKO,
024-361 90 80) within 24 hours using the completed
SAE report. The principal investigators are responsible
for the management of the safety reporting require-
ments according to the local regulations and guidelines.
Copies of all report submissions by the principal investi-
gators to regulatory authorities and to the ethical com-
mittee that has approved the study will be provided to
the pharmacovigilance department of the license holders
of the study drugs. If necessary, additional information
and clarifications on cases will be forwarded to the
license holders by the principal investigator.
An independent monitoring committee will discuss all
reported (serious) adverse events.
Monitoring
A data and safety monitoring board will monitor the
recruitment, the reported serious adverse events and the
data quality at least every 2 months. Relevant informa-
tion will be included in regular study reports, and will
be made available to an Independent Data Monitoring
Committee (IDMC), which will be independent of the
trial organizers.
The IDMC will review the data and safety data on a
regular basis and report their findings to the principal
investigator. The principal investigator will submit these
reports to the ethics committee.
Data quality assurance
Data forms will be entered in the database of the NKI-
AVL Data centre by a double data entry procedure.
Computerized and visual consistency checks will be per-
formed on newly entered forms; queries will be issued
in case of inconsistencies.
On-site quality control
The sponsor will perform on-site monitoring. The mon-
itoring visits will be scheduled at a frequency of about 1
visits per site every 6 months which may be adapted
according to the site accrual.
The aim of on-site visits will be:
-To evaluate the local facilities available to the respon-
sible investigator for performing clinical trials and to
comply to all requirements of the present protocol;
-To assess the consistency of the data reported on the
CRF with the source data (source data verification);
-To check that all SAE’s have been properly reported;
-To resolve all previous unanswered queries.
Interim Analysis
An interim analysis will be conducted 12 months after
all participating hospitals have started the inclusion of
patients or 18 months after inclusion of the first patient.
An independent data monitoring committee (IDMC)
will assess:
1. Safety, especially any unexpectedly high frequency
of serious adverse events;
2. Data compared with previous experience which
are the basis of the current the trial;
3. Any safety or efficacy data that do not justify the
continuation of the trial as planned, including statis-
tically significant differences between treatments.
The IDMC will decide on the impact of any findings
for the continuation of the trial.
Statistical Analysis
All statistical analyses will be done according to the
intention-to-treat principle, i.e. all eligible patients will
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be included in the analysis in the arm to which they
were randomized independently of whether they
received the assigned treatment or not. The final analy-
sis will be performed when 191 events (recurrences or
deaths) will be observed. It is estimated that this will be
possible approximately 1 year after the last patient is
randomized in the study. In the final analysis tables pre-
senting the distribution of the stratification and other
important factors of all cases entered by treatment arm
will be included.
Disease free survival and survival curves will be con-
structed by means of the Kaplan Meier technique.
Curves by treatment arm will be compared using the
log rank test. To adjust for possible confounding factors,
the treatment effect will also be estimated by adjusting
Cox’s proportional hazard regression model.
Clinical and laboratory toxicity graded according NCI-
CTC (version 3.0) will be collected for all patients.
Comparisons by treatment of the continuous variables
will be done by means of Student’s t-test. Comparisons
of categorical date (e.g. grades of toxicity) will be done
by the chi-square test.
Quality of life will be measured using the QLC-C30
questionnaire will be completed by the patients between
surgery and the start of adjuvant treatment and every
6 months thereafter, until 2 years after surgery. Quality
of life assessment is discontinued when adjuvant treat-
ment is discontinued (i.e. in case of progression in arm
A or B or when off-study for any reason).
Changes over time in quality of life items will be eval-
uated with a repeated measurement ANOVA using a
mixed effect modeling procedure (SAS Proc Mixed).
This model allows retaining in the analysis patients who
drop out during follow-up. F-tests are used for testing
main effects of group and time and an interaction effect
of group and time
Sample Size
The primary endpoint of the study is the DFS measured
from randomization. Patients will be randomized just
after R0 resection (+/- RFA). Patients receiving 3 courses
of CAPOX before resection will also be included in the
study. It is expected that about 1/4 of the patients will
have been treated by resection and RFA. The median
DFS is estimated to be 9 months for RFA treated patients
and 20 months in resection treated patients. The median
of the whole mixed group is estimated to be 17 months.
Based on the results in previous recent series, it is
hypothesized that the addition of bevacizumab to
CAPOX would result in a decrease of at least 1/3 of the
hazard of progression (HR = 0.67) [34-36]. The total
number of events that is necessary to provide 80%
power to detect such a decrease, if truly present, with a
2 tailed logrank test at 5% significance is 191. Assuming
an accrual rate of 100 patients per year, a total of 300
patients would be randomized (150 receiving Bevacizu-
mab and 150 not) in 3 years. If all patients are followed
for about 1 year further after accrual is completed, 191
events would be observed and the study will have the
required power.
The total duration of the study would then be 4 years
and patients would have been followed for 1 to 4 years,
depending on whether they were included at beginning
or by the end of the accrual in the study.
Follow-up
Assessments during Study Treatment Phase
-Adverse events will be collected continuously during
the Study Treatment Phase and followed until the event
is either resolved or adequately explained, even after the
patient has completed his/her study treatment.
-Concomitant diseases/treatment and compliance to
study drugs will be monitored continuously during the
Study Treatment Phase.
-History, vital signs, weight, ECOG Performance Status,
urinalysis (dipstick) will be performed at each visit. Toxi-
city assessment, hematology, serum chemistry will be per-
formed at each visit until cycle 8. If dipstick analysis shows
≥2+ protein, 24-hours urine needs to be collected for
accurate measurement of renal protein excretion.
-ECG and chest X-ray will be performed as clinically
indicated.
-Assessment for recurrence (abdominal CT, CEA mea-
surements AND chest CT) will be done after surgery
but before randomization (before cycle 1). Thereafter
every 3 months in the first two years. If the patient
shows signs of a recurrence/new colorectal cancer (e.g.
clinical status OR rising CEA), possible re-operation or/
and further cancer therapy will be recorded.
-Nature and duration of any hospitalization, treatment
of any adverse event and nature and duration of any
outpatient care will be recorded during the Study Treat-
ment Phase.
Assessment during Follow up Phase
-CEA determinations will be done every 3 months after
surgery for the first two years and thereafter every 6
months until a confirmed recurrence/new CRC and at
end of follow-up after 5 years.
-Assessment for recurrence (abdominal CT AND
chest CT) will be done every 3 months for the first two
years after cycle 8 of chemotherapy and every 6 months
thereafter until a confirmed recurrence/new CRC and at
the end of follow-up after 5 years, or if the patient
shows signs of a recurrence/new colorectal cancer (e.g.
clinical status OR rising CEA). Possible re-operation or/
and further cancer therapy will be recorded.
-Extended follow-up of hypertension, proteinuria and
wound healing complication until resolution.
-Additional cancer therapy to be recorded as it occurs.
Snoeren et al. BMC Cancer 2010, 10:545
http://www.biomedcentral.com/1471-2407/10/545
Page 5 of 10
Study medication
Capecitabine
Capecitabine is an oral fluoropyrimidine carbamate ration-
ally designed to generate 5-FU preferentially in tumor
tissue through exploitation of high intratumoral concen-
trations of thymidine phosphorylase (TP), an enzyme pre-
sent at significantly increased concentrations in a wide
range of tumor types, including colorectal, breast and
gastric cancers, compared with normal tissue [37].
Human pharmacokinetic studies have shown that after
oral administration, capecitabine is readily and almost
completely absorbed through the gastro-intestinal wall,
thus avoiding direct intestinal exposure to 5-FU. Capeci-
tabine is metabolized to 5-FU via a three-step enzymatic
cascade, with the final stage of this conversion mediated
by TP [38].
Oxaliplatin
Oxaliplatin is a platinum derivative in which the plati-
num atom is complexed with a 1,2 diaminocyclo-
hexane (DACH) and with an oxolate ligand. It was
synthesized with the goal of trying to overcome resis-
tance to first- and second generation platinum com-
pounds (Sanofi-Synthelabo, 2001). The mechanism of
action of oxaliplatin is similar to that of cisplatin as
well as other platinum (Pt) compounds. Studies con-
ducted to date indicated that the types and percentages
of Pt-DNA adducts formed by oxaliplatin were qualita-
tively similar to those formed by cisplatin, but preclini-
cal data suggested several unique attributes of the
cytotoxic/antitumor activity of oxaliplatin. Oxaliplatin
demonstrated a broad spectrum of in vitro cytotoxicity
and in vivo antitumor activity that differed from that
of either cisplatin or carboplatin. Oxaliplatin was active
against several cisplatin-resistant cell lines, colon carci-
noma and other solid tumors that were not responsive
to cisplatin. In addition, oxaliplatin in combination
with 5-FU led to synergistic antiproliferative activity in
several in vivo models [39].
Bevacizumab
Bevacizumab is a humanized monoclonal antibody tar-
geting vascular endothelial growth factor (VEGF or
VEGF-A) which is a ligand with a central role in signaling
pathways controlling tumor blood vessel development
and survival [40-43]. VEGF binding to cell surface recep-
tors stimulates the process of angiogenesis, the formation
of blood vessels. These receptors, VEGF receptors 1 and
2, are found on vascular endothelial cells. VEGF binding
stimulates endothelial cell proliferation, migration and
survival [41,44,45].
The mode of action of bevacizumab can be summar-
ized as follows:
-Prevents the formation of new blood vessels, thereby
inhibiting the growth of existing tumors and preventing
metastases from developing blood supply.
-Normalizes existing tumor blood vessels. The subse-
quent effects include reduction of the tortuousness of
tumor blood vessels and normalization of vessel perme-
ability. The latter effect is important because tumors
usually exhibit high interstitial pressure which can prevent
chemotherapeutic agents penetrating tumors and acces-
sing tumor cells, where they exert their effects. Normaliza-
tion of permeability, and therefore intratumoral pressure
gradients, thus, promotes chemotherapy access [46].
-Produces blood vessel breakdown, probably through
inhibition of the anti-apoptotic effects of VEGF on
immature endothelial cells. VEGF also has activities
beyond angiogenesis, affecting immune function via inhi-
bition of dendritic cell maturation, formation of lymph
vessels and lymphatic metastasis. All of these actions
indicate that VEGF may be an important target for antic-
ancer drug development. Bevacizumab has proven to be
clinically effective in fase III studies with solid tumors.
Treatment program
Arm A (CAPOX+Bevacizumab) consists of 8 cycles of
CAPOX (either all cycles postoperatively or 3 cycles
preoperatively followed by 5 cycles postoperatively).
Postoperatively patients will be treated with: bevacizu-
mab at 7.5 mg/kg, administered as an intravenous infu-
sion over 20-30 minutes for a maximum of 48 weeks.
CAPOX will be given as follows: oxaliplatin adminis-
tered as a 130 mg/m2 intravenous infusion over 2 hours
(day 1, every 3 weeks) in combination with capecitabine,
which will be administered orally at a dose of 1000 mg/
m2 twice-daily (equivalent to a total daily dose of 2000
mg/m2), with first dose the evening of day 1 and the
last dose the morning of day 15, given as intermittent
treatment (3-week cycles consisting of 2 weeks of treat-
ment followed by 1 week. without treatment). After
completion of the 8 CAPOX cycles, bevacizumab will be
continued as single agent (7.5 mg/kg q3w) treatment.
Bevacizumab will be stopped after 48 weeks
Arm B (CAPOX) consists of 8 cycles of CAPOX
(either all cycles postoperatively or 3 cycles preopera-
tively followed by 5 cycles postoperatively). CAPOX
will be given as follows: Oxaliplatin administered as a
130 mg/m2 intravenous infusion over 2 hours (day 1,
every 3 weeks) in combination with capecitabine, which
will be administered orally at a dose of 1000 mg/m2
twice daily (equivalent to a total daily dose of 2000 mg/
m2), with first dose the evening of day 1 and the last
dose the morning of day 15, given as intermittent treat-
ment (3-week cycles consisting of 2 weeks of treatment
followed by 1 week without treatment).
Discussion
Patients undergoing radical resection or radical resection
in combination with RFA for their colorectal liver
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metastases can be included in this randomized con-
trolled phase III trial where they will receive adjuvant
treatment with CAPOX or CAPOX and bevacizumab.
There has been much debate during the development of
the study whether or not to include a surgery only arm.
There were no results of randomized trials that com-
pared surgery with surgery and adjuvant treatment for
patients with resectable colorectal liver metastases until
November 2006. However, worldwide patients were
commonly treated with adjuvant chemotherapy even in
the absence of positive studies. Portier et al. demon-
strated, in a phase III randomized controlled trial a dis-
ease free survival benefit for surgery and adjuvant
chemotherapy with 5 FU and Leucovorin compared to
surgery alone in patients with resectable colorectal liver
metastases [24]. Nordlinger and colleagues presented
the results of a RCT comparing surgery with surgery
and peri-operative chemotherapy [47]. With this publi-
cation, the debate has shifted towards whether or not to
treat this specific patient group with peri-operative che-
motherapy instead of adjuvant chemotherapy. The
intention to treat analysis of Nordlinger’s study unfortu-
nately demonstrated only a trend in disease free survival
benefit towards the treatment arm. From the results of
this study and previous adjuvant studies it cannot be
concluded that peri-operative chemotherapy is better
than adjuvant chemotherapy. We have amended the
protocol in December 2009 to allow 3 cycles CAPOX to
be administered to bridge time to surgery. However, the
steering committee of the study does feel that adjuvant
treatment unless proven to be inferior of peri-operative
chemotherapy in a randomized trial, is preferred. Since
this amendment, we also allow patients in the study that
undergo resection in combination with RFA. RFA is a
frequently used in addition to resection in patients
where the liver volume is insufficient to resect all tumor
tissue. Since local recurrence is a frequent phenomenon
after RFA in larger tumors we only allow patients with
tumors smaller than 4 cm [20]. Also RFA alone or RFA
for more than 3 tumors is not allowed in the study.
Administering pre-operative chemotherapy to patients
with resectable colorectal liver metastases and thereby
postponing a possible curative treatment seems undesir-
able since there are many disadvantages associated with
neoadjuvant treatment. Neoadjuvant chemotherapy
induces liver toxicity, such as steatosis, steatohepatitis
and sinusoidal changes. Patients receiving pre-operative
chemotherapy increase their chance of post-operative
complications significantly (25% vs 16%) [47] Some
patients undergoing neoadjuvant treatment demonstrate
complete radiologic response. This only translates to
complete pathologic response in 3-4% of the cases [48].
Remarkably complete pathologic response is sometimes
seen in patients demonstrating incomplete radiologic
response. It is therefore well established that all initial
metastases should be resected. Moreover, due to che-
motherapeutic alterations in the liver parenchyma, the
original lesions are difficult to identify. Patients who
progress during chemotherapy might result in inoper-
able patients due to this delay. There is also the danger
of operating on benign lesions. Since there is no demon-
strated benefit of peri-operative chemotherapy compared
to adjuvant treatment, there is no justification to jeopar-
dize resectability. Immediate surgery is preferred and
results in direct control of the hepatic tumor without
additional toxicity and should therefore not be post-
poned when possible. Response to preoperative che-
motherapy could serve as a biological marker for good
prognosis. Nonetheless patients with poor response still
reach 5 year survival. Adjuvant chemotherapy can over-
come many of the disadvantages mentioned above with
equal benefit of increasing DFS. Neoadjuvant treatment
should be preserved for irresectable patients in order to
reduce tumor mass and transfer a substantial number of
patients to resectable. However for resectable patients,
there is no trial comparing a peri-operative regimen
with adjuvant chemotherapy in terms of DFS. Until the
result of such a study demonstrates a benefit for either
arm it seems unjustifiable to postpone a possible cura-
tive treatment.
Because pro-angiogenic factors are upregulated during
liver regeneration it is conceivable that liver regenera-
tion will be inhibited if angiogenesis is inhibited. Clinical
studies show that patients receiving bevacizumab under-
going surgery have more wound healing complications
than patients not receiving bevacizumab (13% vs 3,4%)
[49]. This difference might be explained by the relative
long half life of bevacizumab compared to the com-
pound (PTK/ZK) used in the animal model. Fortunately
a five week interval between bevacizumab treatment and
resection had shown to be sufficient to diminish the
effect on wound heeling and liverregeneration [50].
Unfortunately oxaliplatin has a negative impact on the
liver parenchyma demonstrating in sinusoidal obstruc-
tion syndrome in 20% of all patients [51]. Ribero et al
show in a retrospective study the pathological response
and dilation of sinusoids in the liver of patients who
have been treated with neoadjuvant Folfox in compari-
son with patients who where treated with bevacizumab
and FOLFOX [52]. Forty-three patients received FOL-
FOX and 62 patients received folfox and bevacizumab.
The bevacizumab group showed a significant tumor
regression in comparison with the FOLFOX group.
Remarkably the incidence and severity of sinusoidal dila-
tation reduced in the bevacizumab. This phenomenon
might be due to the fact that oxaliplatin treated sinusoid
cells release MMP-2 and MMP-9 which induce the
destruction of extracellular matrix and degeneration of
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endothelial cells. VEGFG induces the expression of
MMP-9. By inhibiting VEGF, MMP-9 will also be
inhibited.
Conclusion
The HEPATICA study is designed to demonstrate that
adjuvant treatment with the combination of bevacizu-
mab and CAPOX is superior to CAPOX alone as adju-
vant chemotherapy in terms of disease free survival in
patients with colorectal liver metastases.
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